Matthias Guckenberger, Director of the Department of Radiation Oncology at University Hospital Zurich and Professor of Radiation Oncology shared on LinkedIn:
“The Oligo Care study jointly conduced by European Society for Radiotherapy and Oncology (ESTRO) and EORTC – European Organisation for Research and Treatment of Cancer has been a tremendous success with >4000 oligometastatic cancer patients enrolled
This success has only been possible by the support of the Radiation Oncology scientific community
This support by in-kind contributions of the participating institutions and colleagues has now been estimated and published
Looking forward to the primary endpoint analysis and continuing the SPRINT trial within the E2R OligoCare framework”
Title: The Value of Community Engagement in the ESTRO–EORTC OligoCare Project: A Quantification of the In-Kind Contributions
Authors: Davide Cusumano, Alessandro Scaggion, Yolande Lievens, Enrico Clementel, Sarah Nuyens, Filippo Alongi, Sergi Benavente, Pètra Braam, Piet Dirix, Hossein Hemmatazad, Paul Jeene, Barbara Alicja Jereczek-Fossa, Daniela Greto, Sara Ramella, Jasna But-Hadzic, Umberto Ricardi, Juan Salinas, Marta Scorsetti, Igor Sirak, Karin Stellamans, Joachim Widder, Piet Ost, Matthias Guckenberger
You can also read: EXTEND Trial: Histology-Specific Benefits of MDT in Oligometastatic Disease
